SC
JAZZ icon

Syon Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Syon Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$265K Sell
1,403
-305
-18% -$53.3K 0.01% 780
2025
Q4 		$290K Buy
+1,708
New +$262K 0.01% 755

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Syon Capital's JAZZ Position: Q1 2026 in Review

Syon Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 18% in Q1 2026, selling an estimated $53.3K and leaving 1,403 shares worth $265K. The position accounts for 0.01% of the portfolio, ranked #780.

Syon Capital first reported a position in JAZZ in Q4 2025 and has held it in 2 quarters since. The position peaked at $290K in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Syon Capital held 1,403 shares of Jazz Pharmaceuticals worth $265K as of Q1 2026.
  • Syon Capital sold 305 Jazz Pharmaceuticals shares in Q1 2026, an estimated $53.3K.
  • Jazz Pharmaceuticals made up 0.01% of Syon Capital's portfolio in Q1 2026, its #780 holding.
  • Syon Capital first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Syon Capital's Jazz Pharmaceuticals position peaked at $290K in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Syon Capital's 13F filing for Q1 2026, filed 13 May 2026.